Mustang Bio Inc. (MBIO)
NASDAQ (CM) NASDAQ (CM) Primary 
MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy
Mustang Bio surges 180% after its brain cancer therapy, MB-101, earns FDA Orphan Drug status for two rare brain tumor types.
Mustang (MBIO) Soars 477% on Data From Rare Blood Cancer Study
Updated data from a clinical study shows that treatment with Mustang Bio's (MBIO) experimental cell therapy achieved an overall response rate of 90% in patients with a rare form of blood cancer.
Why are Mustang Bio shares (MBIO) up almost 500%?
The Mustang Bio stock price closed on a high yesterday, trading at $0.75. The pharmaceutical company has gone vertical in the past 24 hours, climbing 476.9% to go from $0.13 to $0.75 in a single day.
Why Is Mustang Bio (MBIO) Stock Up 347% Today?
Mustang Bio (NASDAQ: MBIO ) stock is taking off on Monday after the clinical-stage biopharmaceutical company announced positive results from a study. The recent news includes favorable results from the company's Phase 1.2 clinical trial of MB-106.
Why Is Penny Stock Mustang Bio Trading Over 190% On Monday?
Penny stock Mustang Bio Inc MBIO shares are trading higher on a strong session volume of 90 million versus an average volume of 3.17 million, as per data from Benzinga Pro.
Why Is Mustang Bio (MBIO) Stock Up 58% Today?
Mustang Bio (NASDAQ: MBIO ) stock is taking off on Wednesday alongside heavy pre-market trading of the clinical-stage biopharmaceutical company's shares. This has more than 13.9 million shares of MBIO stock changing hands as of this writing.
HC Wainwright Analysts Lower Earnings Estimates for Mustang Bio, Inc. (NASDAQ:MBIO)
Mustang Bio, Inc. (NASDAQ:MBIO – Free Report) – Analysts at HC Wainwright reduced their Q2 2024 earnings estimates for Mustang Bio in a research note issued to investors on Thursday, May 16th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of ($0.14) per share for the quarter, down from their previous estimate of ($0.13). HC Wainwright currently has a “Buy” rating and a $2.00 target price on the stock. The consensus estimate for Mustang Bio’s current full-year earnings is ($1.93) per share. HC Wainwright also issued estimates for Mustang Bio’s Q3 2024 earnings at ($0.13) EPS, Q4 2024 earnings at ($0.16) EPS, FY2024 earnings at ($0.61) EPS and FY2025 earnings at ($0.35) EPS. Mustang Bio Stock Up 4.0 % Shares of NASDAQ:MBIO opened at $0.31 on Monday. The company has a market capitalization of $3.24 million, a price-to-earnings ratio of -0.07 and a beta of 1.75. Mustang Bio has a 52 week low of $0.22 and a 52 week high of $8.17. The firm has a 50 day moving average of $0.61 and a 200 day moving average of $1.13. Mustang Bio (NASDAQ:MBIO – Get Free Report) last issued its quarterly earnings data on Monday, March 11th. The company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($1.68) by $0.97. Hedge Funds Weigh In On Mustang Bio A hedge fund recently bought a new stake in Mustang Bio stock. Armistice Capital LLC acquired a new stake in shares of Mustang Bio, Inc. (NASDAQ:MBIO – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 435,764 shares of the company’s stock, valued at approximately $588,000. Armistice Capital LLC owned about 4.73% of Mustang Bio at the end of the most recent reporting period. Institutional investors and hedge funds own 9.95% of the company’s stock. About Mustang Bio (Get Free Report) Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
